Editas Medicine shelves lead asset after disappointing data

Trending News 🌧️

Editas Medicine Stock Fair Value – Editas Medicine ($NASDAQ:EDIT), a clinical-stage gene editing company, has announced that it is shelving its lead asset after disappointing Phase 1/2 data. The news comes as a blow to the company, which had high hopes for the treatment. CEO Gilmore O’Neill acknowledged the setback, but said that the company still has a strong cash runway and is committed to developing its other assets.

He also said that the data from the trial will be used to inform future research. This is a setback for Editas, but the company is still in a strong position to continue its research and development.

Market Price

Editas Medicine, a gene editing company, announced on Monday that it would be shelving its lead asset after disappointing data. This news sent the stock tumbling, with it opening at $10.8 and closing at $10.3, a drop of 6.1%. This is a major setback for the company, which had hoped that this asset would be its major source of revenue. The data showed that the asset was not as effective as hoped, and this has investors worried about the company’s future.

Editas Medicine will now have to focus on its other assets and try to bring them to market quickly. This will be a difficult task, and the company’s future is now uncertain.

VI Analysis – Editas Medicine Stock Fair Value Calculator

Company’s fundamentals reflect its long term potential, and the VI app makes it easy to see this potential. The intrinsic value of EDITAS MEDICINE shares is around $18.2, which is calculated by the VI Line. The current share price of $10.3 means that the stock is currently undervalued by 43%.

VI Peers

In the world of gene-editing, three companies have emerged as leaders in the race to develop CRISPR-based treatments: Editas Medicine Inc, Intellia Therapeutics Inc, and CRISPR Therapeutics AG. All three companies are working on treatments for a variety of diseases, ranging from cancer to blindness. However, only Editas has begun to clinical trials on humans. This gives them a significant advantage over their competitors. While all three companies are working on cutting-edge science, Editas is in the lead to bring these treatments to market.

– Intellia Therapeutics Inc ($NASDAQ:NTLA)

Intellia Therapeutics Inc is a genomic editing company. Its technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. The company was founded in 2014 and is headquartered in Cambridge, Massachusetts.

As of 2022, Intellia Therapeutics Inc has a market cap of 4.19B and a Return on Equity of -43.06%. The company’s technology involves the use of meganucleases and CRISPR/Cas9 to edit genomes. Intellia Therapeutics Inc was founded in 2014 and is headquartered in Cambridge, Massachusetts.

– CRISPR Therapeutics AG ($NASDAQ:CRSP)

CRISPR Therapeutics AG is a clinical-stage biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases. Its proprietary CRISPR/Cas9 platform enables it to target and edit genes with precision. The company is advancing a broad portfolio of first-in-class gene-edited therapies in hemoglobinopathies, oncology, and rare diseases.

– Beam Therapeutics Inc ($NASDAQ:BEAM)

Beam Therapeutics Inc is a clinical-stage biotechnology company. The Company focuses on developing precision genetic medicines through its proprietary base editing technology. Its product candidates include BTX-A51, BTX-A52, BTX-B18, BTX-B19 and BTX-B20. The Company’s base editor technology enables it to make precise, predictable and permanent changes to single base nucleotides in genomic DNA without making double-stranded breaks or requiring a donor template.

Summary

Investing in Editas Medicine may not be for everyone. While the data was disappointing, Editas Medicine remains committed to developing its other programs and has several other potential candidates in its pipeline.